ReviewDer Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft2015
[Retinal vein occlusion : Epidemiology, classification and clinical findings].
Review in Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 11 citations in OpenAlex.
- [Asymmetric dimethylarginine (ADMA) in retinal vein occlusion-Results from the Gutenberg RVO study].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2021Article
- Intravitreal injection of conbercept combined with retinal photocoagulation on macular edema secondary to branch retinal vein occlusion.Experimental and therapeutic medicine · 2020Article
- Comparison of subfoveal choroidal thickness in eyes with CRVO and BRVO.BMC ophthalmology · 2019Article
- Article
- [Multiple thrombophilic risk markers in patients ≺65 years of age with retinal vein occlusion].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2017Article
- [Incidence of retinal vein occlusion during the football World Cup in 2014 : A database analysis].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since the introduction of intravitreal operative medication injections (IVOM), the therapy of retinal vein occlusion (RVO) has permanently changed. The growing acceptance of IVOM is undoubtedly due to the generally positive outcome after RVO. During the pharmaceutical trials required to obtain medication approval, extensive data were collected on the spontaneous course of the disease and the risk factors responsible for the disease. As RVO is a complication of systemic or local risk factors, these data are also useful for the therapy of the underlying risk factors. In this article the currently available data are presented and evaluated to provide the reader with key guidelines to diagnose and treat this complex syndrome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.